REFERENCES
1. Berardi R, Rinaldi S, Caramanti M, Grohè C, Santoni M, et al. Hyponatremia in cancer patients: time for a new approach. Crit Rev Oncol Hematol 2016;102:15-25.
2. Liamis G, Filippatos TD, Elisaf MS. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol 2016;777:78-87.
3. Ingles Garces AH, Ang JE, Ameratunga M, Chénard-Poirier M, Dolling D, et al. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. Eur J Cancer 2018;104:32-8.
4. Lastraioli E, Iorio J, Arcangeli A. Ion channel expression as promising cancer biomarker. Biochim Biophys Acta 2015;1848:2685-702.
5. Ko JH, Ko EA, Gu W, Lim I, Bang H, et al. Expression profiling of ion channel genes predicts clinical outcome in breast cancer. Mol Cancer 2013;12:106.
6. Schneider EG, Radke KJ, Ulderich DA, Taylor Jr RE. Effect of osmolality on aldosterone secretion. Endocrinology 1985;116:1621-6.
7. Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone “escape”. Hypertension 1984;6:1183-92.
8. Robertson GL. Posterior pituitary. In: Felig P, Baxter J, Frohman L, editors. Endocrinology and Metabolism. New York: McGraw-Hill; 1995. pp. 385-432.
9. Zhang J, Mao W, Dai Y, Qian C, Dong Y, et al. Voltage-gated sodium channel Nav1.5 promotes proliferation, migration and invasion of oral squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai) 2019;51:562-70.
10. Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res 2005;11:5381-9.
11. Sanchez-Sandoval AL, Gomora JC. Contribution of voltage-gated sodium channel β-subunits to cervical cancer cells metastatic behavior. Cancer Cell Int 2019;19:35.
12. Diss JK, Stewart D, Pani F, Foster CS, Walker MM, et al. A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis 2005;8:266-73.
13. Campbell TM, Main MJ, Fitzgerald EM. Functional expression of the voltage-gated Na+-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells. J Cell Sci 2013;126:4939-49.
14. House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, et al. Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res 2010;70:6957-67.
15. Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer 2013;119:3570-7.
16. Otterbach F, Callies R, Adamzik M, Kimmig R, Siffert W, et al. Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas. Breast Cancer Res Treat 2010;120:67-76.
17. Moon C, Soria JC, Jang SJ, Lee J, Obaidul Hoque M, et al. Involvement of aquaporins in colorectal carcinogenesis. Oncogene 2003;22:6699-703.
18. Wang P, Zhang C, Yu P, Tang B, Liu T, et al. Regulation of colon cancer cell migration and invasion by CLIC1-mediated RVD. Mol Cell Biochem 2012;365:313-21.
19. Li A, Lu D, Zhang Y, Li J, Fang Y, et al. Critical role of aquaporin-3 in epidermal growth factor-induced migration of colorectal carcinoma cells and its clinical significance. Oncol Rep 2013;29:535-40.
20. Dou R, Deng Y, Huang L, Fu S, Tan S, et al. Multi-microarray identifies lower AQP9 expression in adjuvant chemotherapy nonresponders with stage III colorectal cancer. Cancer Lett 2013;336:106-13.
21. Liu S, Zhang S, Jiang H, Yang Y, Jiang Y. Co-expression of AQP3 and AQP5 in esophageal squamous cell carcinoma correlates with aggressive tumor progression and poor prognosis. Med Oncol 2013;30:636.
22. Shen L, Zhu Z, Huang Y, Shu Y, Sun M, et al. Expression profile of multiple aquaporins in human gastric carcinoma and its clinical significance. Biomed Pharmacother 2010;64:313-8.
23. Ayaz M, Karabagli H, Yanardag SB. Can hypo/hypernatremic conditions be a factor for Na ion channel kinetics: model study. Turk Neurosurg 2018;28:421-7.
24. Ouwerkerk R, Morgan RH. 23Na MRI: from research to clinical use. J Am Coll Radiol 2007;4:739-41.
25. Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 2003;14:182-7.
26. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist 2012;17:756-65.
27. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 2000;8:192-7.
28. Sengupta A, Banerjee SN, Biswas N M, Jash D, Saha K, et al. The incidence of hyponatraemia and its effect on the ECOG performance status among lung cancer patients. J Clin Diagn Res 2013;7:1678-82.
29. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the subcommittee for the management of lung cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990;61:597-604.
30. Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol 2014;65:723-30.
31. Berardi R, Caramanti M, Fiordoliva I, Morgese F, Savini A, et al. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. Support Care Cancer 2015;23:621-6.
32. Kim HS, Yi SY, Jun HJ, Lee J, Park JO, et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 2007;73:192-7.
33. Choi JS, Bae EH, Ma SK, Kweon SS, Kim SW. Prognostic impact of hyponatraemia in patients with colorectal cancer. Colorectal Dis 2015;17:409-16.
34. Dhaliwal HS, Rohatiner AZ, Gregory W, Richards MA, Johnson PW, et al. Combination chemotherapy for intermediate and high grade non-Hodgkin’s lymphoma. Br J Cancer 1993;68:767-74.
35. Jeppesen AN, Jensen HK, Donskov F, Marcussen N, von der Maase H. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 2010;102:867-72.
36. Berardi R, Santoni M, Newsom-Davis T, Caramanti M, Rinaldi S, et al. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget 2017;8:23871-9.
37. Berardi R, Caramanti M, Castagnani M, Guglielmi S, Marcucci F, et al. Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support Care Cancer 2015;23:3095-101.
38. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013;126:S1-42.
39. Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238:97-110.
40. Berardi R, Santoni M, Rinaldi S, Nunzi E, Smerilli A, et al. Risk of hyponatraemia in cancer patients treated with targeted therapies: a systematic review and meta-analysis of clinical trials. PLoS One 2016;11:e0152079.
41. Sata A, Hizuka N, Kawamata T, Hori T, Takano K. Hyponatremia after transsphenoidal surgery for hypothalamo-pituitary tumors. Neuroendocrinology 2006;83:117-22.
43. Gillum DM, Linas SL. Water intoxication in a psychotic patient with normal renal water excretion. Am J Med 1984;77:773-4.
44. Hillier TA, Abbott RD, Berrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999;106:399-403.
45. Peri A, Grohé C, Berardi R, Runkle I. SIADH: differential diagnosis and clinical management. Endocrine 2017;55:311-9.
46. Cuesta M, Garrahy A, Thompson CJ. SIAD: practical recommendations for diagnosis and management. J Endocrinol Invest 2016;39:991-100.
47. Petereit C, Zaba O, Teber I, Luders H, Grohe C. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm Med 2013;13:55.
48. Berardi R, Armento G, Barni S, Caramanti M, Morgese F, et al. Disordini elettrolitici: raccomandazioni per l’iter diagnostic-terapuetico nel paziente oncologico. AIOM 2018. Available from: https://www.aiom.it/wp-content/uploads/2018/11/2018_Raccomandazioni_disordini_elettrolitici_AIOM.pdf [Last accessed on 26 Nov 2019].
50. Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm 2005;62:1663-82.
51. Snyder NA, Feigal DW, Arieff AI. Hypernatremia in elderly patients. A heterogenous, morbid, and iatrogenic entity. Ann Intern Med 1987;107:309-19.
52. Kahn T. Hypernatremia in hospitalized patients: a sequel of inadvertent fluid administration - reply. Arch Intern Med 2000;160:1537-8.
53. Gipstein RM, Boyle JD. Hypernatremia complicating prolonged mannitol diuresis. N Engl J Med 1965;272:1116-7.
54. Loh JA, Verbalis JG. Diabetes insipidus as a complication after pituitary surgery. Nat Clin Pract Endocrinol Metab 2007;3:489-94.
55. Lindner G, Kneidinger N, Holzinger U, Druml W, Schwarz C. Tonicity balance in patients with hypernatremia acquired in the intensive care unit. Am J Kidney Dis 2009;54:674-9.
57. Liamis G, Filippatos TD, Elisaf MS. Evaluation and treatment of hypernatremia: a practical guide for physicians. Postgrad Med 2016;128:299-306.
58. Rose BD. Clinical physiology of acid-base and electrolyte disorders. 5th ed. New York: Mcgraw-Hill; 2001.
59. Palevsky PM. Hypernatraemia. In: Greenberg A, editor. Primer on Kidney Diseases. 2nd ed. San Diego: Academic Press; 1998. pp. 64-71.
60. Sands JM, Bichet DG; American College of P, American Physiological S. Nephrogenic diabetes insipidus. Ann Intern Med 2006;144:186-94.
61. Bailey RL, Dodd KW, Goldman JA, Gahche JJ, Dwyer JT, et al. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010;140:817-22.
62. Ashajyothi A, Pippalla RS, Satyavati D. Osteoporosis - an overview. IJPT 2010;2:847-61.
63. Carney SL. Calcitonin and human renal calcium and electrolyte transport. Miner Electrolyte Meta 1997;23:43-7.
65. Rizzuto R, Pozzan T. Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol Rev 2006;86:369-408.
66. Grice DM, Vetter I, Faddy HM, Kenny PA, Roberts-Thomson SJ, et al. Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. J Biol Chem 2010;285:37458-66.
67. Vanden Abeele F, Zholos A, Bidaux G, Shuba Y, et al. Ca2+-independent phospholipase A2-dependent gating of TRPM8 by lysophospholipids. J Biol Chem 2006;281:40174-82.
68. Chodon D, Guilbert A, Dhennin-Duthille I, Gautier M, Telliez MS, et al. Estrogen regulation of TRPM8 expression in breast cancer cells. BMC Cancer 2010;10:212.
69. Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H. Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 2003;22:7858-61.
70. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993;22:363-75.
71. Zhu W, Zhong M, Ai Z. Systematic evaluation of prophylactic neck dissection for the treatment of papillary thyroid carcinoma. Jpn J Clin Oncol 2013;43:883-8.
72. Kukreja SC, Shanmugam A, Lad TE. Hypocalcemia in patients with prostate cancer. Calcif Tissue Int 1998;43:340-5.
73. McCormick BB, Davis J, Burns KD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012;60:626-8.
74. Hanamura M, Iwamoto T, Soga N, Sugimura Y, Okuda M. Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor. Biol Pharm Bull 2010;33:721-4.
75. Wang Q, Qi Y, Zhang D, Gong C, Yao A, et al. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol 2015;36:3471-82.
76. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993;22:363-75.
77. Favus MJ, Bushinsky DA, Lemann JJ. Chapter 13. Regulation of calcium, magnesium, and phosphate metabolism. Am Soc Bone Miner Res 2006. Available from: http://www.homepages.ucl.ac.uk/~ucgatma/Anat3048/PAPERS%20etc/ASBMR%20Primer%20Ed%206/Ch%2013-18%20-%20Mineral%20Homeostasis.pdf [Last accessed on 26 Nov 2019].
80. Schafer AL, Shoback DM. Hypocalcemia: diagnosis and treatment. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, et al, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2016. Available from: http://www.ncbi.nlm.nih.gov/books/NBK279022/. [Last accessed on 26 Nov 2019].
81. Maeda SS, Fortes EM, Oliveira UM, Borba VC, Lazaretti-Castro M. Hypoparathyroidism and pseudohypoparathyroidism. Arq Bras Endocrinol Metabol 2006;50:664-73.
82. Schäffler A. Hormone replacement after thyroid and parathyroid surgery. Dtsch Arztebl Int 2010;107:827-34.
83. Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 2016;101:2273-83.
84. Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician 2012;58:158-62.
86. Bundred N. Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev 2012;38:776-86.
87. Sava L, Pillai S, More U, Sontakke A. Serum calcium measurement: total versus free (ionized) calcium. Indian J Clin Biochem 2005;20:158-61.
89. Medas F, Erdas E, Loi G, Podda F, Pisano G, et al. Controversies in the management of parathyroid carcinoma: a case series and review of the literature. Int J Surg 2016;28 Suppl 1:S94-8.
90. Saunders BD, Saunders EF, Gauger PG. Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg 2009;33:2314-23.
91. Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis 2014;63:141-7.
92. Liou JH, Cho LC, Hsu YH. Paraneoplastic hypercalcemia with metastatic calcification - clinicopathologic studies. Kaohsiung J Med Sci 2006;22:85-8.
93. Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, et al. TGF-β promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling. Cancer Res 2011;71:822-31.
94. Stewart AF, Adler M, Byers CM, Segre GV, Broadus AE. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med 1982;306:1136-40.
95. Wesson LC, Suresh V, Parry RG. Severe hypercalcaemia mimicking acute myocardial infarction. Clin Med (Lond) 2009;9:186-7.
97. Hagerty DR. Evidence-based treatment of hypercalcemia. Medescape 2009. Available from: https://www.medscape.com/viewarticle/702842 [Last accessed on 26 Nov 2019].
98. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981;50:473-81.
99. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008;149:259-63.
100. Austin LA, Heath H 3rd. Calcitonin: physiology and pathophysiology. N Engl J Med 1981;304:269-78.
101. Dumon JC, Magritte A, Body JJ. Nasal human calcitonin for tumor-induced hypercalcemia. Calcif Tissue Int 1992;51:18-9.
102. Strumpf M, Kowalski MA, Mundy GR. Effects of glucocorticoids on osteoclast-activating factor. J Lab Clin Med 1978;92:772-8.
103. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14:1468-76.
104. Schwartz LM, Woloshin S. Lost in transmission - FDA drug information that never reaches clinicians. N Engl J Med 2009;361:1717-20.
105. Zacchia M, Abategiovanni ML, Stratigis S, Capasso G. Potassium: from physiology to clinical implications. Kidney Dis (Basel) 2016;2:72-9.
106. Eleftheriadis T, Leivaditis K, Antoniadi G, Liakopoulos V. Differential diagnosis of hyperkalemia: an update to a complex problem. Hippokratia 2012;16:294-302.
107. Gennari FJ. Disorders of potassium homeostasis. Hypokalemia and hyperkalemia. Crit Care Clin 2002;18:273-88.
108. Clausen T, Everts ME. Regulation of the Na, K-pump in skeletal muscle. Kidney Int 1989;35:1-13.
109. Haren N, Khorsi H, Faouzi M, Ahidouch A, Sevestre H, et al. Intermediate conductance Ca2+ activated K+ channels are expressed and functional in breast adenocarcinomas: correlation with tumour grade and metastasis status. Histol Histopathol 2010;25:1247-55.
110. Altintas DM, Allioli N, Decaussin M, de Bernard S, Ruffion A, et al. Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS One 2013;8:e66278.
111. Girault A, Privé A, Trinh NT, Bardou O, Ferraro P, et al. Identification of KvLQT1 K+ channels as new regulators of non-small cell lung cancer cell proliferation and migration. Int J Oncol 2014;44:838-48.
112. Crociani O, Zanieri F, Pillozzi S, Lastraioli E, Stefanini M, et al. hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. Sci Rep 2013;3:3308.
113. Ding XW, Wang XG, Luo HS, Tan SY, Gao S, et al. Expression and prognostic roles of Eag1 in resected esophageal squamous cell carcinomas. Dig Dis Sci 2008;53:2039-44.
114. Lastraioli E, Perrone G, Sette A, Fiore A, Crociani O, et al. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Br J Cancer 2015;112:1076-87.
115. Shao XD, Wu KC, Guo XZ, Xie MJ, Zhang J, et al. Expression and significance of HERG protein in gastric cancer. Cancer Biol Ther 2008;7:45-50.
116. Ding XW, Yang WB, Gao S, Wang W, Li Z, et al. Prognostic significance of hERG1 expression in gastric cancer. Dig Dis Sci 2010;55:1004-10.
117. Crociani O, Lastraioli E, Boni L, Pillozzi S, Romoli MR, et al. hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications. Clin Cancer Res 2014;20:1502-12.
118. Ma Y, Hou L, Yu F, Lu G, Qin S, et al. Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer. Oncotarget 2017;8:18417-23.
119. Viens P, Thyss A, Garnier G, Ayela P, Lagrange M, et al. GM-CSF treatment and hypokalemia. Ann Intern Med 1989;111:263.
120. Adams PC, Woodhouse KW, Adela M, Parnham A. Exaggerated hypokalaemia in acute myeloid leukaemia. Br Med J (Clin Res Ed) 1981;282:1034-5.
122. Bendlow J, Apps E, Jones LE, Poston GJ. Carcinoid syndrome. Eur J of Surg Oncol 2008;34:289-96.
123. Ikuta S, Yasui C, Kawanaka M, Aihara T, Yoshie H, et al. Watery diarrhea, hypokalemia and achlorhydria syndrome due to an adrenal pheochromocytoma. World J Gastroenterol 2007;13:4649-52.
124. Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2001;970:134-44.
125. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, et al; Participants of the German Conn’s Registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry. J Clin Endocrinol Metab 2009;94:1125-30.
126. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, et al; Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007;110:1376-84.
127. Filippatos TD, Milionis HJ, Elisaf MS. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol 2005;75:449-60.
128. Yamamoto Y, Akashi Y, Minami T, Nozawa M, Kiba K, et al. Serious hypokalemia associated with abiraterone acetate in patients with castration-resistant prostate cancer. Case Rep Urol 2018;2018:1414395.
130. Kishimoto C, Tamaru K, Kuwahara H. Tall P waves associated with severe hypokalemia and combined electrolyte depletion. J Electrocardiol 2014;47:93-4.
131. Viera AJ, Wouk N. Potassium disorders: hypokalemia and hyperkalemia. Am Fam Physician 2015;92:487-95.
132. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, et al. Protective role of magnesium in the cardiovascular diseases: a review. Mol Cell Biochem 2002;238:163-79.
133. Castro D, Sharma S. Hypokalemia. StatPearls Publishing; 2019.
134. Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. Arch Intern Med 1990;150:613-7.
135. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 2007;18:2649-52.
136. Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas 2011;40:987-94.
137. Su H, Gu Y, Li F, Wang Q, Huang B, et al. The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism. PLoS One 2013;8:e62399.
138. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454-62.
139. Pessi MA, Zilembo N, Haspinger ER, Molino L, Di Cosimo S, et al. Targeted therapy-induced diarrhea: a review of the literature. Crit Rev Oncol Hematol 2014;90:165-79.
140. Charytan D, Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Arch Intern Med 2000;160:1605-11.
141. Nagasaki A, Takamine W, Takasu N. Severe hyperkalemia associated with “alternative” nutritional cancer therapy. Clin Nutr 2005;24:864-5.
142. Metzner J, Evans JL, Domino KB. Life-threatening hyperkalemia during radiofrequency ablation of hepatocellular carcinoma. J Clin Anesth 2010;22:473-6.
143. Liamis G, Filippatos TD, Elisaf MS. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol 2016;777:78-87.
144. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 2007;103:363-7.
145. Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010;149:578-86.
146. Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol 2002;56:95-101.
147. Bellevue R, Dosik H, Spergel G, Gussoff BD. Pseudohyperkalemia and extreme leukocytosis. J Lab Clin Med 1975;85:660-4.
148. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 2000;18:721-9.
151. Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci 2014;347:93-100.
153. Ngugi NN, McLigeyo SO, Kayima JK. Treatment of hyperkalaemia by altering the transcellular gradient in patients with renal failure: effect of various therapeutic approaches. East Afr Med J 1997;74:503-9.
155. Grašič Kuhar C, Strojan P, Zadnik V, Zakotnik B. Importance of magnesium sulfate supplementation in the prevention of hypomagnesemia and hypocalcemia during chemoradiation in head and neck cancer. J Trace Elem Med Biol 2018;50:327-31.
156. Rubeiz GJ, Thill-Baharozian M, Hardie D, Carlson RW. Association of hypomagnesemia and mortality in acutely ill medical patients. Crit Care Med 1993;21:203-9.
157. Lajer H, Kristensen M, Hansen HH, Nielsen S, Frøkiaer J, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 2005;56:535-42.
158. Wang Q, Qi Y, Zhang D, Gong C, Yao A, et al. Electrolyte disorders assessment insolid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol 2015;36:3471-82.
159. Yu ASL. Disturbances of magnesium metabolism. In: Brenner BM, Rector FC, editors. The Kidney. Saunders 6th ed, Philadelphia; 2000. pp. 1055-70.
161. Noronha JL, Matuschak GM. Magnesium in critical illness: metabolism, assessment, and treatment. Intensive Care Med 2002;28:667-79.
164. Morisaki H, Yamamoto S, Morita Y, Kotake Y, Ochiai R, et al. Hypermagnesemia-induced cardiopulmonary arrest before induction of anesthesia for emergency cesarean section. J Clin Anesth 2000;12:224-6.
